Ryvu Therapeutics

Ryvu Therapeutics is a Polish clinical-stage biotech focused on discovering and developing targeted small molecule therapies for cancer. Its strategy centers on tackling difficult-to-drug targets through a proprietary, integrated R&D platform, yielding a pipeline with both wholly-owned and partnered assets. Key achievements include advancing its lead program RVU120 into Phase I/II trials for hematological malignancies and securing a strategic partnership with BioNTech for its HPK1 inhibitor. The company aims to become a leader in precision oncology by translating novel biological insights into differentiated therapeutics.

An integrated drug discovery platform combining structural biology, computational chemistry, and medicinal chemistry expertise to generate novel small molecules against difficult-to-drug targets, particularly in immuno-oncology and signaling pathways.

Ryvu faces direct competition in XPO1 inhibition from Karyopharm and others, in STING agonists from major pharma, and in HPK1 from several clinical-stage competitors. Its differentiation relies on achieving superior safety/efficacy profiles with its next-generation candidates.